drugset / Trial / NCT05636150
A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Investigators conduct the clinical trial to further explore the efficacy and safety of Fruquintinib combined with S-1 in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments.
Timeline
- Start
- 2022-03-30
- Primary completion
- 2024-03-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 3 mg | Oral |
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |